PureTech’s Deupirfenidone Gains Orphan Drug Status for IPF in U.S. and EU
Event summary
- PureTech’s deupirfenidone (LYT-100) received Orphan Drug Designation from the FDA and European Commission for treating idiopathic pulmonary fibrosis (IPF).
- Phase 2b trial data showed deupirfenidone slowed lung function decline more effectively than existing treatments.
- Celea Therapeutics, a PureTech subsidiary, plans to initiate a Phase 3 trial (SURPASS-IPF) in the first half of 2026.
The big picture
PureTech’s Orphan Drug Designation for deupirfenidone underscores the unmet need in IPF treatment, where only a quarter of patients receive approved therapies due to tolerability and efficacy tradeoffs. The designation accelerates development timelines and provides market exclusivity, positioning deupirfenidone as a potential disruptor in the fibrotic lung disease space. The strategic move aligns with PureTech’s model of advancing late-stage assets through subsidiary entities like Celea Therapeutics.
What we're watching
- Clinical Validation
- Whether Phase 3 trial results will confirm deupirfenidone’s superiority over existing IPF treatments.
- Regulatory Pathway
- The pace at which the FDA and EMA will review deupirfenidone for potential approval.
- Commercialization Strategy
- How Celea Therapeutics will secure financing and execute the Phase 3 trial to position deupirfenidone as a new standard of care.
Related topics